However, half of the identified pathogenic HDR gene variants in EC patients were in BRCA1 or BRCA2, which calls for counseling in regard of breast and ovarian cancer risk in some 2% of EC patients and their family members from Kazakhstan. This evidence concerns the gene BRCA2 and ovarian cancer.